Van De Velde A L R, Anguille S, Berneman Z N
Antwerp University Hospital, Division of Haematology, Edgem, Belgium.
Acta Clin Belg. 2012 Nov-Dec;67(6):399-402. doi: 10.2143/ACB.67.6.2062703.
Therapeutic cancer vaccination, e.g. by using tumour antigen-presenting dendritic cells (DCs) that 'educate' the immune system to recognise and attack tumour cells, represents a new concept of treatment in oncology. DCbased immunotherapy elicits both innate (NK) and adaptive (T cells) cellular responses correlated with clinical benefit. WT1 mRNA-transfected DCs emerge as a feasible and effective strategy to control residual disease in acute myeloid leukaemia (AML), in particular as a post-remission treatment to prevent full relapse. This innovative approach takes advantage of the intrinsic potential of the immune system to eradicate malignant disease.
治疗性癌症疫苗接种，例如通过使用能够“训练”免疫系统识别并攻击肿瘤细胞的肿瘤抗呈递树突状细胞（DC），代表了肿瘤学治疗的一个新概念。基于DC的免疫疗法引发了与临床益处相关的先天性（自然杀伤细胞）和适应性（T细胞）细胞反应。WT1信使核糖核酸转染的DC成为控制急性髓系白血病（AML）残留疾病的一种可行且有效的策略，尤其是作为缓解后预防完全复发的治疗方法。这种创新方法利用了免疫系统根除恶性疾病的内在潜力。
